Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 65
- Registration Number
- NCT01835678
- Locations
- 🇩🇪
Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Nuremberg, Germany
Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 678
- Registration Number
- NCT01826370
- Locations
- 🇵🇭
Boehringer Ingelheim Investigational Site 42, Cardona, Rizal, Philippines
🇵🇭Boehringer Ingelheim Investigational Site 24, Las Pinas, Philippines
🇵🇭Boehringer Ingelheim Investigational Site 25, Cebu, Philippines
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 607
- Registration Number
- NCT01734785
- Locations
- 🇪🇸
1275.9.34011 Boehringer Ingelheim Investigational Site, A Coruña, Spain
🇪🇸1275.9.34009 Boehringer Ingelheim Investigational Site, Alicante, Spain
🇳🇴1275.9.47006 Boehringer Ingelheim Investigational Site, Svelvik, Norway
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT01703286
- Locations
- 🇩🇪
1218.105.001 Boehringer Ingelheim Investigational Site, Neuss, Germany
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 45
- Registration Number
- NCT01617824
- Locations
- 🇮🇹
University Hospital Diabetes Outpatient Clinic, Padova, Italy
Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT01581931
- Locations
- 🇩🇪
1288.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Marcus Borchert
- Target Recruit Count
- 40
- Registration Number
- NCT01547104
- Locations
- 🇩🇪
ikfe GmbH, Mainz, Rhineland-Palatinate, Germany
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 316
- Registration Number
- NCT01512979
- Locations
- 🇺🇸
1218.83.11022 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸1218.83.11013 Boehringer Ingelheim Investigational Site, Jacksonville, North Carolina, United States
🇺🇸1218.83.11017 Boehringer Ingelheim Investigational Site, Chattanooga, Tennessee, United States
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
- Conditions
- Interventions
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 689
- Registration Number
- NCT01438814
- Locations
- 🇧🇪
1218.60.32001 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇧🇪1218.60.32005 Boehringer Ingelheim Investigational Site, Ham, Belgium
🇧🇪1218.60.32004 Boehringer Ingelheim Investigational Site, Natoye, Belgium
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1405
- Registration Number
- NCT01422876
- Locations
- 🇺🇸
1275.1.01043 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
🇺🇸1275.1.01039 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸1275.1.01003 Boehringer Ingelheim Investigational Site, Shreveport, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.